Literature DB >> 35532795

Discovering biomarkers for hormone-dependent tumors: in silico study on signaling pathways implicated in cell cycle and cytoskeleton regulation.

Klaudia Waszczykowska1, Karolina Prażanowska1, Żaneta Kałuzińska2, Damian Kołat3, Elżbieta Płuciennik3.   

Abstract

Malignancies dependent on hormone homeostasis include breast, ovary, cervical, prostate, testis and uterine tumors. Hormones are involved in signal transduction which orchestrate processes, such as apoptosis, proliferation, cell cycle or cytoskeleton organization. Currently, there is a need for novel biomarkers which would help to diagnose cancers efficiently. In this study, the genes implicated in signaling that is important in hormone-sensitive carcinogenesis were investigated regarding their prognostic significance. Data of seven cancer cohorts were collected from FireBrowse. 54 gene sets implicated in specific pathways were browsed through MSig database. Profiling was assessed via Monocle3, while gene ontology through PANTHER. For confirmation, correlation analysis was performed using WGCNA. Protein-protein networks were visualized via Cytoscape and impact of genes on survival, as well as cell cycle or cytoskeleton-related prognostic signatures, was tested. Several differences in expression profile were identified, some of them allowed to distinguish histology. Functional annotation revealed that various regulation of cell cycle, adhesion, migration, apoptosis and angiogenesis underlie these differences. Clinical traits, such as histological type or cancer staging, were found during evaluation of module-trait relationships. Of modules, the TopHubs (COL6A3, TNR, GTF2A1, NKX3-1) interacted directly with, e.g., PDGFB, ITGA10, SP1 or AKT3. Among TopHubs and interacting proteins, many showed an impact on hazard ratio and affected the cell cycle or cytoskeleton-related prognostic signatures, e.g., COL1A1 or PDGFB. In conclusion, this study laid the foundation for further hormone-sensitive carcinogenesis research through identification of genes which prove that crosstalk between cell cycle and cytoskeleton exists, opening avenues for future therapeutic strategies.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Biomarkers; Cell cycle; Cytoskeleton; Hormone-dependent cancers; Signaling pathways

Mesh:

Substances:

Year:  2022        PMID: 35532795     DOI: 10.1007/s00438-022-01900-7

Source DB:  PubMed          Journal:  Mol Genet Genomics        ISSN: 1617-4623            Impact factor:   3.291


  104 in total

Review 1.  Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy.

Authors:  F Chang; J T Lee; P M Navolanic; L S Steelman; J G Shelton; W L Blalock; R A Franklin; J A McCubrey
Journal:  Leukemia       Date:  2003-03       Impact factor: 11.528

Review 2.  The Wnt/β-catenin pathway in ovarian cancer: a review.

Authors:  Rebecca C Arend; Angelina I Londoño-Joshi; J Michael Straughn; Donald J Buchsbaum
Journal:  Gynecol Oncol       Date:  2013-10-11       Impact factor: 5.482

Review 3.  SWI/SNF chromatin remodeling complexes and cancer.

Authors:  Jaclyn A Biegel; Tracy M Busse; Bernard E Weissman
Journal:  Am J Med Genet C Semin Med Genet       Date:  2014-08-28       Impact factor: 3.908

Review 4.  Estrogens and breast cancer: Mechanisms involved in obesity-related development, growth and progression.

Authors:  Priya Bhardwaj; CheukMan C Au; Alberto Benito-Martin; Heta Ladumor; Sofya Oshchepkova; Ruth Moges; Kristy A Brown
Journal:  J Steroid Biochem Mol Biol       Date:  2019-03-06       Impact factor: 4.292

Review 5.  Wnt signalling and the actin cytoskeleton.

Authors:  T Akiyama; Y Kawasaki
Journal:  Oncogene       Date:  2006-12-04       Impact factor: 9.867

6.  Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells.

Authors:  Filippo Acconcia; Christopher J Barnes; Rakesh Kumar
Journal:  Endocrinology       Date:  2005-12-08       Impact factor: 4.736

7.  Molecular subtypes of uterine leiomyosarcoma and correlation with clinical outcome.

Authors:  Joyce N Barlin; Qin C Zhou; Mario M Leitao; Maria Bisogna; Narciso Olvera; Karin K Shih; Anders Jacobsen; Nikolaus Schultz; William D Tap; Martee L Hensley; Gary K Schwartz; Jeff Boyd; Li-Xuan Qin; Douglas A Levine
Journal:  Neoplasia       Date:  2015-02       Impact factor: 5.715

8.  Patterns of cell cycle checkpoint deregulation associated with intrinsic molecular subtypes of human breast cancer cells.

Authors:  Jacquelyn J Bower; Leah D Vance; Matthew Psioda; Stephanie L Smith-Roe; Dennis A Simpson; Joseph G Ibrahim; Katherine A Hoadley; Charles M Perou; William K Kaufmann
Journal:  NPJ Breast Cancer       Date:  2017-03-31

9.  The landscape of somatic copy-number alteration across human cancers.

Authors:  Rameen Beroukhim; Craig H Mermel; Dale Porter; Guo Wei; Soumya Raychaudhuri; Jerry Donovan; Jordi Barretina; Jesse S Boehm; Jennifer Dobson; Mitsuyoshi Urashima; Kevin T Mc Henry; Reid M Pinchback; Azra H Ligon; Yoon-Jae Cho; Leila Haery; Heidi Greulich; Michael Reich; Wendy Winckler; Michael S Lawrence; Barbara A Weir; Kumiko E Tanaka; Derek Y Chiang; Adam J Bass; Alice Loo; Carter Hoffman; John Prensner; Ted Liefeld; Qing Gao; Derek Yecies; Sabina Signoretti; Elizabeth Maher; Frederic J Kaye; Hidefumi Sasaki; Joel E Tepper; Jonathan A Fletcher; Josep Tabernero; José Baselga; Ming-Sound Tsao; Francesca Demichelis; Mark A Rubin; Pasi A Janne; Mark J Daly; Carmelo Nucera; Ross L Levine; Benjamin L Ebert; Stacey Gabriel; Anil K Rustgi; Cristina R Antonescu; Marc Ladanyi; Anthony Letai; Levi A Garraway; Massimo Loda; David G Beer; Lawrence D True; Aikou Okamoto; Scott L Pomeroy; Samuel Singer; Todd R Golub; Eric S Lander; Gad Getz; William R Sellers; Matthew Meyerson
Journal:  Nature       Date:  2010-02-18       Impact factor: 49.962

10.  Identification of integrin drug targets for 17 solid tumor types.

Authors:  Adith S Arun; Clifford G Tepper; Kit S Lam
Journal:  Oncotarget       Date:  2018-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.